Certain Omnipod® Insulin Management System pods (including Omnipod, Omnipod DASH, Omnipod 5 and listed model/catalogue numbers POD‑ZXR425, ZXR420, POD‑OMNI‑I1‑6729/6720, POD‑BLE‑C1‑520/529 and lot/serial numbers L72521, L72516, PH1U01222522 and others listed by the manufacturer) are recalled after tears were found in the external soft cannula near the bottom housing window. The cannula tear can compromise insulin delivery, potentially causing high blood glucose and, in severe cases, diabetic ketoacidosis. Owners should discontinue use of any impacted pod immediately and, if the pod in use is from an affected lot, change it and confirm the replacement is not from an affected lot; see the manufacturer’s notice for details.
What's being recalled
Companies: Insulet Corporation, 100 Nagog Park, Acton, Massachusetts, United States, 01720.
How to identify it
Affected products: Omnipod® Insulin Management System - Omnipod®; Lot or serial number: L72521; Model or catalogue number: ZXR420
Affected products: Omnipod® Insulin Management System - Omnipod®; Lot or serial number: L72516; Model or catalogue number: POD-ZXR425
Affected products: Omnipod® 5 Automated Insulin Delivery System 10-Pack Pods; Lot or serial number: PH1U01222522; Model or catalogue number: POD-OMNI-I1-6729
Affected products: Omnipod® DASH®; Lot or serial number: More than 10 numbers, contact manufacturer.; Model or catalogue number: POD-BLE-C1-520
Affected products: Omnipod® DASH®, Pods 10-Pack; Lot or serial number: More than 10 numbers, contact manufacturer.; Model or catalogue number: POD-BLE-C1-529
Affected products: Omnipod® 5 Pod; Lot or serial number: PH1U01222522; Model or catalogue number: POD-OMNI-I1-6720
The hazard
The defect is related to tears on the external (exposed) soft cannula. The defect is consistently located near the bottom housing window, with similar physical appearance and tear orientation across devices. The cannula tear may result in a compromised fluid path due to damage to the cannula, leading to potential reduced or interrupted insulin delivery. If insulin is not delivered properly, user may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), a serious medical condition that requires prompt medical treatment and can be life-threatening if not treated. To identify the impacted product and lot number, users will be asked to review the notification letter and follow the instructions: Discontinue use of any impacted pod immediately. If the pod the user is currently using, is from an affected lot, it is important that the user immediately changes the pod to resume insulin delivery. When changing the pod, confirm that the new pod is not from an affected lot.
What to do
For further details on this recall, please refer to the manufacturer’s website at: https://www.omnipod.com/en-ca/fsn-5-26
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)